MedTrace Logo

Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma

NCT00897923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2017-03-22

No results posted yet for this study

Summary

RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma tumors may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future.

PURPOSE: This study is measuring radiolabeled white blood cells in patients with non-Hodgkin's lymphoma.

Conditions

Interventions

PROCEDURE

radionuclide imaging

RADIATION

indium In 111-labeled autologous peripheral blood mononuclear cells

RADIATION

indium In 111-labeled autologous polymorphonuclear leukocytes

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Gregory Wiseman, MD · Mayo Clinic

  • Michael M. Graham, PhD, MD · Holden Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2012-02-10
Completion
2012-02-10

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897923 on ClinicalTrials.gov